We are entering the era of personalized medicine, in which pharmacogenomics and biomarker-based assays can be used to tailor diagnostic tests and drug therapies to individual patients. This new approach to patient-specific care offers the potential to maximize the efficacy of available medical treatments while reducing the incidence of adverse side effects. Here, we present approaches to personalize the care of heart transplant recipients.
INTRODUCTION
Over 2000 years ago, Hippocrates stated that 'it is more important to know what person the disease has than what disease the person has'. Modern medicine is finally fulfilling this prophecy, with a renewed focus on personalized medicine -a novel model in which medical decisions and practices are tailored to individual patients. There is perhaps no field in medicine that stands to benefit more from personalized medicine than transplantation. In the case of heart transplantation, early mortality has decreased significantly in the past 2 decades [1] ; long-term survival has not improved appreciably, however, and late mortality is often attributed to side effects of immunosuppressive therapy, such as infectious complications, renal failure, and malignancy [1] . There is now substantial evidence that genomic variation in the host leads to differences in the immune response and susceptibility to adverse outcomes [2] . We know, for example, that most drugs are either ineffective or incompletely effective in 30-60% of patients [3, 4] , which is of critical importance to transplant recipients who are treated with a large number of medications to suppress the immune response and prevent posttransplant complications. The ability to tailor medical therapy offers the potential to increase treatment efficacy, improve long-term outcomes, reduce adverse events, and improve patient satisfaction and compliance. This article reviews recent advances in personalized therapies after heart transplantation.
Pharmacogenomic approaches to personalized posttransplant care
The medications used for maintenance of immunosuppression in heart transplant recipients include long-term use of a calcineurin inhibitor (tacrolimus or cyclosporine) in almost all cases, an antimetabolite [usually mycophenolate mofetil (MMF)], and in some cases a proliferation signal inhibitor (sirolimus or everolimus). There is now substantial evidence for individual variability with respect to drug pharmacokinetics and side effects to these powerful and often toxic drugs. It is estimated that genetics can account for 20-95% of variability in drug disposition and side effects [5] .
Tacrolimus is inactivated in the liver by cytochrome P450 enzymes in the 3A family (CYP3A). Polymorphisms in the CYP3A5 gene have been found to correlate with tacrolimus dose requirements. Patients with the CYP3A5Ã1 polymorphism have lower tacrolimus trough levels despite higher doses [6] . This CYP3A5Ã1 polymorphism is present in 65% of African-Americans, compared with 8% of non-African-Americans, which explains why most African-American patients require higher tacrolimus doses to achieve target trough levels and may contribute to the increased risk of allograft rejection observed in this patient group. Similarly, tacrolimus is a substrate for the drug transporter P-glycoprotein, encoded by the gene ABCB1. Homozygosity for the C allele of the synonymous rs1045642 variant has been associated with lower serum tacrolimus levels [7] . In contrast to tacrolimus, studies linking genetic polymorphisms in CYP3A and Pglycoprotein to drug concentrations have not shown an association with cyclosporine dose requirement [8, 9] . Despite this potential advantage, use of cyclosporine is decreasing due to data indicating a higher incidence of acute rejection with cyclosporine compared with tacrolimus [10] .
Rather than adopting a blanket protocol for use of a particular calcineurin inhibitor (usually tacrolimus) [1] for all patients, transplant centers may do well to tailor the selection of an individual agent based on the patient's medical history and rejection risk profile. For example, the incidence of hypertension and hyperlipidemia appears to be higher with cyclosporine than tacrolimus, whereas this drug confers a lower risk of new-onset diabetes mellitus, tremor, and gastrointestinal effects [2] . In addition, cyclosporine, unlike tacrolimus, may cause gingival hyperplasia and hirsutism, which may represent a significant barrier to its use.
Similarly, the side effects caused by MMF, such as diarrhea and leukopenia, are common and lead to dose reduction or discontinuation of therapy in approximately 15% of treated patients [11] . Genetic predisposition has been shown to influence MMF adverse events [12, 13] .
Given these examples, and others, it is increasingly clear that some of the disparity seen in transplant outcomes may be attributed to biological factors conferred by genetic differences. Compared with white recipients, for example, black recipients have a higher burden of genetic variants predisposing to inflammation, which may require more intensive maintenance immunosuppression [2, 14] . Use of predictive models that incorporate clinical and genetic risk factors to personalize therapy therefore hold particular promise for posttransplant care.
Posttransplant immune monitoring
At present, immunosuppressive treatment is mainly protocol-driven and is not selected on the basis of individual immune alloreactivity. Similarly, immunosuppressive drug doses are guided mainly by the achievement of target drug concentrations in peripheral blood and by the development of side effects. Blood levels of calcineurin inhibitors are measured; however, their primary value is for preventing drug toxicity and not in determining the immune response state. MMF blood levels are not routinely assessed, and there is no reliable method to assess the immunosuppressive influence of corticosteroids on the individual patient. Furthermore, there is no tool that can accurately assess the additive effects of different medications on the overall immune response of an individual patient. Our current strategy may therefore lead to either underimmunosuppression, resulting in acute rejection, or overimmunosuppression, resulting in opportunistic infections, malignancy, renal dysfunction, and other toxicities. Thus, a comprehensive immune function assay is greatly needed for immune monitoring, regardless of the immunosuppressive regimen adopted.
Such an immune monitoring assay (ImmuKnow; Viracor Eurofins, Lee's Summit, MO, USA) has been approved by the US Food and Drug Administration for quantification of cell-mediated immunity in immunosuppressed populations [15] . Immune monitoring measures adenosine triphosphatase (ATP) release from activated lymphocytes and correlates with the overall level of immune responsiveness. In a prospective study, 296 heart transplant
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recipients had a total of 864 immune monitoring assays performed at 2 weeks to 10 years posttransplant that were correlated with infection and rejection events within 1 month after immune monitoring testing. There were 38 infections and eight rejection events, and the mean immune monitoring score was significantly lower during infection than at steady state (187 vs. 280 ng ATP/ ml, P < 0.001). The average immune monitoring score was not significantly different during rejection, when compared with steady state, perhaps due to the small number of rejection events. Overall, immune monitoring offers several advantages over other measures of immune function. For example, although immune monitoring scores can predict the risk for developing infection in transplant recipients, there was little correlation between immune monitoring scores and immunosuppressive drug levels due to the fact that each patient has their own unique response to immunosuppression. The same tacrolimus level of 8 ng/ml in two heart transplant recipients might reflect immune monitoring scores of 200 and 400 ng ATP/ml, respectively, illustrating the patients' different immune responses to the drug.
Another novel approach to assessment of the overall immune response is measurement of Torque teno virus (TTV) load, quantified via sequencing of cell-free DNA (cfDNA) from the blood of transplant recipients. A recent study quantified the relative genomic abundance of viral DNA fragments in the plasma of heart and lung transplant patients [16 & ]. By far, the most abundant component of the plasma virome consisted of TTVs, members of the Anelloviridae family. TTV infections are nearly ubiquitous in humans, with primary infection early in childhood [17] . Infection is usually asymptomatic and does not result in any known, clinically significant disease. For both heart and lung transplants, a striking positive relationship was observed between the abundance of TTV sequences in plasma and overall level of immunosuppression: TTV viral loads increased dramatically during the first 6 months posttransplant and subsequently declined with weaning of immunosuppressive therapy. This observation raises the question of whether TTV load can be used to gauge immunocompetence. Consistent with this hypothesis are recent studies demonstrating the association between TTV viral loads and rejection [16 & ,18 & ] (Fig. 1) as well as opportunistic infection [19] .
More recently, a proof-of-concept study was performed in which a molecular barcode-based immune repertoire sequencing assay that sensitively and accurately measures the isotype and clonal composition of the B-cell antibody repertoire was used to monitor pharmacologically induced immunosuppression in a small cohort of heart transplant recipients [18 & ]. The antibody heavy chain immunoglobulin H transcript is unique as its expression changes in abundance and in sequence when a B cell is activated. Activated B cells express high levels of mutated antibodies of the IgG and IgA isotypes, whereas naïve B cells express nonmutated IgM antibodies at low levels. A lower abundance of classswitched sequences indicates a lower number of activated B cells and, consequently, lower activity of the adaptive immune response. After analysis of 130 plasma samples from 12 patients, with an average follow-up period of 15 months, Vollmers et al. concluded that immune repertoire sequencing enables the measurement of a patient's net state of immunosuppression (correlation with tacrolimus level, r ¼ À0.87) as well as the diagnosis of acute allograft rejection, which is preceded by increased immune activity, with a sensitivity of 71% and a specificity of 82%.
These studies illustrate the use of novel assays for assessment of the aggregate impact of multiple immunosuppressive medications. Such knowledge will enable assessment of an individual patient's immune response to better predict the risk of acute rejection, opportunistic infection, or other drug toxicities and will pave the way toward personalized immunosuppressive therapies. 
Noninvasive assessment of acute rejection
Enhanced detection of acute rejection through noninvasive means has the potential to dramatically improve posttransplant care, both by increasing patient satisfaction and by avoiding invasive procedures [20] . A major step in the development of a noninvasive test for acute cellular rejection (ACR) was the multicenter CARGO study [21] , which used iterative validation steps involving hundreds of patient blood samples and corresponding biopsies to identify 11 genes expressed by peripheral blood mononuclear cells that reliably distinguished ACR from immunologic quiescence. The assay employs an algorithm that yields an expression score between 0 and 40, with higher scores (!34) indicating a higher likelihood of acute rejection. This gene expression test, known commercially as the AlloMap Molecular Expression test (CareDx, Brisbane, California, USA) became available for clinical use in January 2005 for use in stable patients who were at least 2 months posttransplant. Subsequently, the IMAGE clinical trial was launched to evaluate patient outcomes using the AlloMap test as the primary means of ACR surveillance [22] . In this multicenter study, 602 patients were randomized to surveillance using AlloMap or endomyocardial biopsy, with a primary outcome of first occurrence of rejection with hemodynamic compromise, graft dysfunction, death, or retransplantation. The trial investigators found that the incidence of the primary outcome was similar in the AlloMap and biopsy groups (14.5% and 15.3%, respectively). Notably, the AlloMap group had 67% fewer biopsies and higher patient satisfaction. Since publication of IMAGE, many heart transplant centers in the United States have adopted AlloMap testing as their primary means of ACR surveillance. However, significant criticisms of the AlloMap assay remain, including its low positive predictive value and the fact that it is contraindicated for use in patients deemed to be at high risk of adverse events.
Since publication of IMAGE, there has been interest in the use of within-patient variability of AlloMap scores to predict future clinical events and thereby personalize posttransplant care. The 'AlloMap score variability (AMV)' was defined as the SD of four AlloMap scores collected at least 315 days posttransplant. In a retrospective analysis of the CARGO II trial [23] , the negative predictive value for an adverse event (death, retransplant, or graft failure) with an AMV score of 0.6 was 97% [95% confidence interval (CI) 91.4-100.0], whereas the positive predictive value for an AMV score of 1.5 was 35.4% (95% CI 13.5-75.8) [23] . Use of the AMV assay for individualized care has not been widely adopted, however, due to the need for at least four AlloMap scores collected at least 315 days posttransplant, at a time when routine acute rejection surveillance is performed infrequently, and the fact that there is a long lag time between the calculation of an AMV score and a potential clinical event.
More recently, cfDNA has emerged as a promising means to interrogate the health of the allograft, thereby providing a direct, sensitive means to assess for allograft injury. In 2011, a multidisciplinary group at Stanford University introduced a method to quantify donor-derived cfDNA (ddcfDNA) in the circulation of a transplant recipient. This approach takes advantage of single-nucleotide polymorphisms (SNPs) distributed across the genome to discriminate donor and recipient DNA molecules. The concept was first successfully demonstrated in a retrospective study in heart transplantation, in which increased levels of donor-derived DNA were shown to correlate with ACR events as determined by endomyocardial biopsy [24] .
The utility of dd-cfDNA in monitoring acute rejection was subsequently tested in a prospective study performed at Stanford University in 65 de novo heart transplant recipients [25 & ]. Pretransplant SNP genotyping and posttransplant shotgun sequencing of cfDNA were used to quantify donor and recipient-specific SNPs. The investigators demonstrated that dd-cfDNA is markedly elevated on postoperative day 1 (up to 10%), reflecting early ischemia-reperfusion injury after transplant surgery, and subsequently falls to a very low baseline level (<0.1%) within several days, whereupon this low baseline is maintained in the absence of rejection. Comparison with endomyocardial biopsy showed that dd-cfDNA was significantly elevated at the time of acute rejection (Fig. 2) . Analysis of the performance of dd-cfDNA in distinguishing moderate-tosevere rejection from quiescence yielded an area under the curve of 0.83 (sensitivity of 58%, specificity of 93% at a threshold of 0.25%). This study also demonstrated the potential for early diagnosis of rejection via cfdDNA monitoring: the level of ddcfDNA was significantly elevated several weeks to months prior to rejection diagnosis by biopsy.
Of great importance in the era of personalized medicine is the fact that dd-cfDNA is a quantitative marker that can be trended over time [26] . This feature may be used to guide therapeutic decisions. For example, the level of dd-cfDNA may be used to inform medication dose titration. In the case of acute rejection, immunosuppression may be augmented when initial signs of graft injury appear, indicated by an early rise in dd-cfDNA levels, thereby potentially preventing the occurrence of a clinical rejection event. Furthermore, close monitoring of dd-cfDNA during immunosuppressive dose reduction may enable safe weaning of therapy in stable patients, thereby preventing the consequences of long-term overimmunosuppression. Finally, dd-cfDNA may be used to assess the response to treatment for acute rejection, thus enabling early assessment of treatment efficacy and reducing the need for follow-up biopsies.
Significant progress has already been made with respect to cfDNA testing, due to widespread interest in this technique: alternative measurements of ddcfDNA based on targeted sequencing [27, 28] and digital PCR [29] have been introduced that offer the promise of lower assay cost and faster turnaround time. CareDx, Inc. has developed AlloSure -a dd-cfDNA assay that uses a panel of 266 highly polymorphic SNPs to distinguish donor from recipient cfDNA without requiring whole genome sequencing. The performance of this assay in the clinical setting is currently being tested in 23 heart transplant centers in the United States in a CareDxsponsored registry study.
Personalized prophylaxis against opportunistic infections
Spanish heart transplant centers have led the way in developing protocols for targeted opportunistic infection prophylaxis. This approach is important due to the relatively low incidence of several opportunistic infections, drug-related toxicities and interactions, high medication costs, and potential emergence of drug resistance. In a prospective cohort study, Muñoz et al. selectively administered antifungal prophylaxis to only 10% of their de novo heart transplant recipients based on the presence of risk factors for invasive aspergillosis: re-operation, posttransplant hemodialysis, cytomegalovirus (CMV) disease, and a case of invasive aspergillosis in their program within the prior 2 months. This group demonstrated high efficacy and safety of targeted prophylaxis, with a reduction in the incidence of invasive aspergillosis and Aspergillus-related mortality [30] . Another Spanish center retrospectively analyzed their clinical outcomes using a preemptive strategy of routine CMV monitoring followed by initiation of antiviral therapy when viral replication was first detected, rather than universal anti-CMV prophylaxis, and reported a low incidence of CMV disease (4.6%) in their patient cohort [31] . Although there are no data available from randomized clinical trials to support the use of preemptive therapy or universal prophylaxis, studies such as this suggest that individualized infection prevention strategies may play an important role in the care of heart transplant recipients.
CONCLUSION
In the 19th century, Sir William Osler (1849-1919) of Johns Hopkins Hospital (Baltimore, Maryland, USA) dedicated his life's work toward making the correct diagnosis and the right choice and dose of drugs to benefit the patient as an individual. As he famously said, 'If it were not for the great variability among individuals, medicine might well have been a science and not an art' [32] . Unfortunately, our current healthcare model continues to be expensive, reactive, inefficient, and focuses largely on 'onesize-fits-all' treatments. Adopting therapeutic plans that account for pharmacogenomics as well as individual patient risk factors for adverse events (such as age [33] , sex, degree of pretransplant sensitization, and medical comorbidities) will enable us to derive the maximum benefit from available therapies while avoiding their adverse consequences. Moreover, research in the '-omic' sciences has greatly improved understanding of the relationships between genes, proteins, and diseases, providing important tools for personalized medicine. This collection of biologic information, as applied to understanding transplantation, has been coined 'transplantomics' [34] and offers the potential to select optimal therapies, prescribe safer dosing options, improve patient safety, reduce inappropriate testing and procedures, FIGURE 2. Performance of donor-derived cell-free DNA as a marker for heart transplant rejection. Box plots of the fraction of donor-derived cell-free DNA for stable heart transplant recipients (biopsy grade 0), recipients diagnosed with mild rejection (1R/1A grade < 2R/3A), and recipients diagnosed with moderate-to-severe rejection (grade ! 2R/3A or antibody mediated rejection). Reproduced from [25
